Medy-Tox Crecimiento futuro

Future controles de criterios 4/6

Medy-Tox se prevé un crecimiento anual de los beneficios y los ingresos de 74.4% y 21.5% respectivamente. Se prevé que el BPA sea de grow en 75.5% al año. Se prevé que la rentabilidad de los fondos propios sea de 15.2% en 3 años.

Información clave

75.6%

Tasa de crecimiento de los beneficios

73.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	40.8%
Tasa de crecimiento de los ingresos	18.0%
Rentabilidad financiera futura	13.7%
Cobertura de analistas	Good
Última actualización	11 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

KOSDAQ:A086900 - Estimaciones futuras de los analistas y datos financieros pasados (KRW Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	315,643	70,856	56,000	64,766	6
12/31/2024	251,916	43,445	5,333	27,357	5
12/31/2023	221,121	8,780	-23,947	13,522	N/A
9/30/2023	205,386	10,346	-10,459	21,773	N/A
6/30/2023	200,043	25,877	-1,798	30,079	N/A
3/31/2023	198,012	36,545	-13,797	13,915	N/A
12/31/2022	195,096	36,035	1,099	26,199	N/A
9/30/2022	182,052	23,216	6,700	29,848	N/A
6/30/2022	198,617	30,632	7,983	32,684	N/A
3/31/2022	192,805	43,052	24,942	47,932	N/A
12/31/2021	184,870	93,179	-1,378	19,966	N/A
9/30/2021	175,194	89,727	-37,235	-6,137	N/A
6/30/2021	141,110	69,059	-20,333	-1,541	N/A
3/31/2021	138,761	31,503	-34,575	-7,150	N/A
12/31/2020	140,828	-29,577	-16,379	27,927	N/A
9/30/2020	169,531	-12,877	14,421	50,326	N/A
6/30/2020	182,101	-9,739	-1,676	43,616	N/A
3/31/2020	195,537	6,671	-3,132	39,623	N/A
12/31/2019	205,900	26,206	10,039	33,703	N/A
9/30/2019	191,069	43,578	20,512	42,313	N/A
6/30/2019	190,954	54,898	21,904	39,389	N/A
3/31/2019	190,887	62,348	27,467	39,296	N/A
12/31/2018	205,445	69,964	43,049	55,071	N/A
9/30/2018	215,001	72,978	55,864	66,876	N/A
6/30/2018	207,067	71,844	45,960	70,852	N/A
3/31/2018	199,573	74,394	38,760	72,113	N/A
12/31/2017	181,239	70,106	12,976	56,546	N/A
9/30/2017	168,236	65,816	N/A	44,835	N/A
6/30/2017	160,927	67,142	N/A	48,247	N/A
3/31/2017	144,971	62,573	N/A	55,349	N/A
12/31/2016	133,256	59,231	N/A	54,101	N/A
9/30/2016	118,090	55,656	N/A	48,000	N/A
6/30/2016	108,114	51,536	N/A	37,272	N/A
3/31/2016	98,465	47,367	N/A	35,453	N/A
12/31/2015	88,505	42,293	N/A	22,356	N/A
9/30/2015	78,066	37,393	N/A	21,963	N/A
6/30/2015	87,180	48,726	N/A	37,679	N/A
3/31/2015	81,388	45,602	N/A	34,354	N/A
12/31/2014	75,892	43,628	N/A	105,379	N/A
9/30/2014	70,699	41,200	N/A	103,756	N/A
6/30/2014	48,631	22,938	N/A	85,950	N/A
3/31/2014	43,640	18,419	N/A	84,684	N/A
12/31/2013	39,141	14,304	N/A	16,596	N/A
9/30/2013	40,719	13,762	N/A	12,621	N/A
6/30/2013	39,790	14,192	N/A	12,496	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: A086900(74.4% al año) es superior a la tasa de ahorro (2.3%).

Beneficios frente mercado: A086900Se prevé que los beneficios de la empresa (74.4% al año) crezcan más deprisa que el mercado KR (32.7% al año).

Beneficios de alto crecimiento: A086900Se espera que los beneficios de la empresa crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: A086900Se prevé que los ingresos de la empresa (21.5% al año) crezcan más deprisa que los del mercado KR (9.6% al año).

Ingresos de alto crecimiento: A086900Se prevé que los ingresos de la empresa (19% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): A086900Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (15.2%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Medy-Tox Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 7.0% to ₩296,000

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 33%, revenue upgraded

Price target increased by 16% to ₩330,000

Consensus EPS estimates increase by 29%

Price target increased by 28% to ₩177,429

Recent updates

Medy-Tox's (KOSDAQ:086900) Anemic Earnings Might Be Worse Than You Think

Price target decreased by 7.0% to ₩296,000

Medy-Tox Inc., Annual General Meeting, Mar 29, 2024

Medy-Tox Inc., Annual General Meeting, Mar 29, 2024

Medy-Tox Inc., Annual General Meeting, Mar 29, 2024

Medy-Tox Inc.'s (KOSDAQ:086900) Prospects Need A Boost To Lift Shares

Consensus EPS estimates increase by 14%

New minor risk - Profit margin trend

Consensus EPS estimates fall by 33%, revenue upgraded

Upcoming dividend of ₩952 per share at 0.4% yield

Investor sentiment improves as stock rises 23%

Price target increased by 16% to ₩330,000

Consensus EPS estimates increase by 29%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 17%

Price target increased by 28% to ₩177,429

Investor sentiment improves as stock rises 27%

Consensus forecasts updated

Now 20% undervalued

Less than half of directors are independent

Consensus EPS estimates increase by 71%

Investor sentiment improved over the past week

Consensus forecasts updated

Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index (USD)

Consensus forecasts updated

Investor sentiment improved over the past week

Consensus forecasts updated

Consensus forecasts updated

Now 22% undervalued after recent price drop

Now 21% undervalued

Consensus forecasts updated

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus forecasts updated

Price target decreased to ₩152,333

Price target decreased to ₩165,429

Upcoming dividend of ₩1,000 per share

Price target decreased to ₩207,250

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase to ₩12,541

Price target increased to ₩246,362

Investor sentiment improved over the past week

Medy-Tox Inc. announced that it has received KRW 64.99993078 billion in funding

Medy-Tox Inc. announced that it expects to receive KRW 64.99993078 billion in funding

Tread With Caution Around Medy-Tox Inc.'s (KOSDAQ:086900) 0.4% Dividend Yield

Price target raised to ₩221,214

A Look At Medy-Tox's (KOSDAQ:086900) Share Price Returns

New 90-day low: ₩130,900

Read This Before Buying Medy-Tox Inc. (KOSDAQ:086900) For Its Dividend

New 90-day low: ₩163,500

Price target lowered to ₩169,749

Upcoming Dividend of ₩777 Per Share

New 90-day high - ₩272,900

Price target raised to ₩199,900

Price target lowered to ₩179,200

Analysts update estimates

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento